Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer

被引:5
|
作者
da Silva, Fernanda Cardoso [1 ]
Brandao, Douglas Cardoso [1 ]
Ferreira, Everton Allan [2 ]
Siqueira, Raoni Pais [1 ]
Ferreira, Helen Soares Valenca [1 ]
Da Silva Filho, Ademar Alves [2 ]
Araujo, Thaise Goncalves [1 ,3 ]
机构
[1] Univ Fed Uberlandia, Inst Biotechnol, Lab Genet & Biotechnol, BR-38700002 Patos De Minas, MG, Brazil
[2] Univ Fed Juiz de Fora, Fac Pharm, Dept Pharmaceut Sci, BR-36036900 Juiz De Fora, MG, Brazil
[3] Univ Fed Uberlandia, Inst Biotechnol, Lab Nanobiotechnol Prof Dr Luiz Ricardo Goulart Fi, BR-38405302 Uberlandia, MG, Brazil
关键词
breast cancer; hormone therapy; natural products; resistance; CELL-CYCLE ARREST; ESTROGEN-RECEPTOR-ALPHA; ENDOCRINE THERAPY RESISTANCE; NF-KAPPA-B; GROWTH-FACTOR; TUMOR-GROWTH; IN-VITRO; MAMMARY-GLAND; UP-REGULATION; MCF-7; CELLS;
D O I
10.3390/ph16101466
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Breast cancer (BC) is the most diagnosed cancer worldwide, mainly affecting the epithelial cells from the mammary glands. When it expresses the estrogen receptor (ER), the tumor is called luminal BC, which is eligible for endocrine therapy with hormone signaling blockade. Hormone therapy is essential for the survival of patients, but therapeutic resistance has been shown to be worrying, significantly compromising the prognosis. In this context, the need to explore new compounds emerges, especially compounds of plant origin, since they are biologically active and particularly promising. Natural products are being continuously screened for treating cancer due to their chemical diversity, reduced toxicity, lower side effects, and low price. This review summarizes natural compounds for the treatment of luminal BC, emphasizing the activities of these compounds in ER-positive cells. Moreover, their potential as an alternative to endocrine resistance is explored, opening new opportunities for the design of optimized therapies.
引用
收藏
页数:40
相关论文
共 50 条
  • [31] Histology of Luminal Breast Cancer
    Erber, Ramona
    Hartmann, Arndt
    BREAST CARE, 2020, 15 (04) : 327 - 336
  • [32] Adjustment after 'TAILORing': Changing the narrative of breast cancer treatment
    Wilson, Elaine
    Hickey, Tina
    McKeon, Kay
    PSYCHO-ONCOLOGY, 2020, 29 : 31 - 31
  • [33] Tailoring breast cancer treatment to genetic status: The challenges ahead
    Daly, MB
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) : 1776 - 1777
  • [34] Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust
    Piccart, M. J.
    Kalinsky, K.
    Gray, R.
    Barlow, W. E.
    Poncet, C.
    Cardoso, F.
    Winer, E.
    Sparano, J.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1077 - 1082
  • [35] Perspectives on breast cancer management: Tailoring treatment to the individual patient
    Thomssen, Christoph
    BREAST CARE, 2008, 3 : 21 - 23
  • [36] Natural cures for breast cancer treatment
    Shareef, Munazza
    Ashraf, Muhammad Aqeel
    Sarfraz, Maliha
    SAUDI PHARMACEUTICAL JOURNAL, 2016, 24 (03) : 233 - 240
  • [37] Luminal Metastatic Breast Cancer
    Huober, Jens
    Bartsch, Rupert
    Marme, Frederik
    Pagani, Olivia
    Thomssen, Christoph
    BREAST CARE, 2019, 14 (02) : 99 - 101
  • [38] Potential natural compounds for chemoprevention of breast cancer: Identification of herbal/dietary aromatase inhibitors.
    Sarter, B
    Kwok, SL
    Hur, G
    Weitzel, J
    Chen, S
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (11) : 1884S - 1884S
  • [39] LncRNAs in tumor microenvironment: The potential target for cancer treatment with natural compounds and chemical drugs
    Liu, Qiu-Ping
    Lin, Jia-Yi
    An, Pei
    Chen, Yu-Ying
    Luan, Xin
    Zhang, Hong
    BIOCHEMICAL PHARMACOLOGY, 2021, 193
  • [40] Inhibition and potential treatment of colorectal cancer by natural compounds via various signaling pathways
    Wang, Mingchuan
    Liu, Xianjun
    Chen, Tong
    Cheng, Xianbin
    Xiao, Huijie
    Meng, Xianglong
    Jiang, Yang
    FRONTIERS IN ONCOLOGY, 2022, 12